Stellantis CEO Antonio Filosa to Participate in Goldman Sachs 17th Annual Industrials & Autos Week AMSTERDAM, December 1, 2025 – Stellantis CEO Antonio Filosa will participate in a fireside chat on Thursday, December 4, 2025, from 3:05 p.m. to 3:40 p.m. CET / 9:05 a.m. to 9:40 a.m. EST at Goldman Sachs 17th Annual Industrials & Autos Week. To watch the live session, visit the following webcast link: https://kvgo.com/gs/stellantis-december-2025 Details for watching the fireside chat are also available unde ...

MIAMI, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Standard Premium Finance Holdings, Inc. (OTCQX: SPFX) (“Standard Premium”), a leading specialty finance company, announces new state licensing approvals that expand its operating footprint to 40 states. In 2025, Standard Premium received approvals in New Jersey, New York, North Dakota, Pennsylvania and Utah. These states join the company’s 2024 expansion into Connecticut, Michigan, Rhode Island, Montana, New Mexico and Oregon, further solidifying Standard Premium’s p ...

ATLANTA, GA, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Trust Stamp announced a Turnkey Solution to Violent Crypto-Focused Home Invasions and “Wrench Attacks.” A recent attack in San Francisco, where a criminal posing as a delivery driver tied up a homeowner and forced an $11 million crypto transfer, has highlighted a growing wave of home invasions involving kidnappings, beatings, and even torture. The home invasions target cryptocurrency holders exploiting a fatal flaw in today’s digital-asset ecosystem: criminals ...

Core Insights - ALK has appointed Edward Jordan as the new Executive Vice President and head of Commercial Operations in North America, effective January 5, 2026, succeeding Søren Niegel [1] - The elevation of ALK's two key commercial regions, Europe and North America, into the Executive Leadership Team aims to strengthen the execution of ALK's Allergy+ strategy [1] Company Overview - ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma, manufacturing and marketing allergy immunotherapy treatments and acute anaphylaxis treatments [5] - The company is headquartered in Hørsholm, Denmark, employs around 2,800 people worldwide, and is listed on Nasdaq Copenhagen [5] Leadership Background - Edward Jordan brings over 30 years of biopharmaceutical experience, with expertise in allergy and immunology, having worked with companies like Merck, Teva Pharmaceuticals, and DBV Technologies [2] - His experience includes leading commercial strategy, product launches, and market development, particularly in the North American market [2] Strategic Focus - President & CEO Peter Halling emphasized the importance of strong commercial execution following recent product launches, highlighting Jordan's extensive experience in commercial growth and market insights [3] - Jordan expressed his commitment to strengthening commercial execution to expand access and adoption of ALK's products across North America [3] Executive Leadership Team Composition - Following the appointment of Edward Jordan, the Executive Leadership Team now includes various executives responsible for different operational areas, reinforcing the company's strategic focus [7]

Coop Pank AS (the Bank) is making preparations for the buy-back of own shares. The purpose of buy-back of own shares is the acquisition of the shares necessary for exercising the option programme. According to the current plan, the shares will be acquired in the volume of up to 3% of all the shares of the Bank. There are two pre-conditions for the buy-back of own shares – relevant resolution of the General Meeting of shareholders of the Bank and respective permission by the Estonian Financial Supervision A ...

Core Insights - Gildan Activewear Inc. has completed the acquisition of HanesBrands Inc., establishing itself as a global leader in the apparel industry [1][2] - The acquisition is expected to double Gildan's scale and enhance its capabilities in activewear and innerwear, providing a strong platform for innovation and growth [2] Company Overview - Gildan is a prominent manufacturer of everyday basic apparel, offering products such as activewear, underwear, socks, and intimates to a diverse customer base including wholesale distributors and global lifestyle brands [3] - The company markets its products under a variety of owned brands, including Gildan, Hanes, and Champion, across multiple regions including North America, Europe, Asia Pacific, and Latin America [3] Manufacturing and ESG Practices - Gildan operates large-scale, vertically integrated manufacturing facilities primarily located in Central America, the Caribbean, North America, and Asia [4] - The company is committed to industry-leading labor, environmental, and governance practices, which are integral to its long-term business strategy and ESG initiatives [4] Integration and Synergies - Gildan aims to achieve at least $200 million in run-rate cost synergies from the integration of HanesBrands, emphasizing the importance of a seamless and collaborative integration process [2]

NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (Nasdaq: NDAQ) (“Nasdaq” or the “Company”) today announced its offers to purchase for cash in the order of priority set forth in the table below (the “Acceptance Priority Levels”) up to an aggregate purchase price of $95,000,000 (excluding Accrued Interest (as defined below)) (the “Maximum Tender Payment”) for its outstanding Notes, subject to (i) a sub-cap of $80,000,000 in aggregate principal amount (the “2028 Notes Cap”) of the Company’s 5.350% Sen ...

Core Insights - MAIA Biotechnology, Inc. announced that its CEO and certain board members purchased approximately 182,445 shares of the company's common stock at an average price of $1.06 between November 21 and 28, 2025 [1][2] Company Overview - MAIA is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, specifically its lead program, ateganosine (THIO), which targets telomerase-positive cancer cells in non-small cell lung cancer (NSCLC) patients [4] Recent Developments - Vlad Vitoc, M.D., the Chairman and CEO, purchased 94,300 shares at an average price of $1.08, while other board members Cristian Luput and Stan V. Smith, Ph.D., purchased a combined total of 88,145 shares at an average price of $1.04 [2] - The company reported a 38% response rate and an overall survival of 17.8 months in its Phase 2 THIO-101 clinical trial, indicating the potential of ateganosine to improve patient outcomes [3] Management Confidence - The management expressed confidence in the ongoing clinical development of ateganosine, highlighting its potential to become a new standard of care for patients with non-small cell lung cancer [3] - Board members emphasized the strategic focus and scientific momentum of the company, suggesting it is well-positioned to deliver significant value for shareholders in the future [3]

PLAINVIEW, N.Y., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Veeco Instruments Inc. (NASDAQ: VECO) today announced that a leading semiconductor memory company has selected Veeco’s laser spike annealing (LSA system) for evaluation in its advanced DRAM R&D group. This shipment marks an expansion of Veeco’s penetration into the DRAM market and represents a significant step toward high-volume manufacturing (HVM) adoption for next-generation DRAM and high bandwidth memory (HBM) technologies. The evaluation period is expec ...

Polarean’s FDA cleared coil achieves important milestone, expanding clinical reach XENOVIEW® 3T coil passes Philips compatibility testing XENOVIEW® 3T Chest Coil is now confirmed for integration with Philips MRI systems starting in 2026 DURHAM, NC and LONDON, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging ("MRI") of the lungs, announces that its FDA-cleared XENOVIEW® 3T Chest Coil has successfully complet ...